Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PF00562271

Small molecule · developed by Verastem

Phase 1 Most advanced trial (none active)
VSTM Developer
1 Registered trials

What is PF00562271?

PF00562271 is a tablet taken at 125 mg twice daily with food. It is studied in head and neck neoplasms, prostatic neoplasms and pancreatic neoplasms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Verastem, Inc. (VSTM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00666926 Phase 1 Head and Neck Neoplasm Completed VSTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck NeoplasmPancreatic NeoplasmProstatic Neoplasm

More from Verastem

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the VSTM page.

Follow VSTM, the company behind PF00562271

See VSTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VSTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.